Sidewinder Therapeutics is focused on engineering next-generation bispecific ADCs that target tumor-specific receptor co-complexes to enhance tumor specificity and internalization. The company’s pipeline targets indications including squamous cell carcinomas of the lung and head and neck and gastrointestinal cancers such as colorectal cancer. Sidewinder was founded in 2023 and is headquartered in San Diego. It has partnered with Lonza to apply Synaffix’s site-specific linker‑payload platform across multiple programs. The company plans to advance its lead program into clinical development in 2027. Financially, Sidewinder has raised a total of $162 million following the $137 million Series B.

Total raised

$137M

Funding rounds

1

Latest round

Series B

Latest activity

Apr 2026